Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver disease, including non-alcoholic fatty liver (NAFL) and its more progressive form, non-alcoholic steatohepatitis (NASH). The prevalence of NAFLD/NASH along with type 2 diabetes and obesity is rising worldwide. In those w...

Descripción completa

Detalles Bibliográficos
Autores principales: Karim, Gres, Bansal, Meena B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2023
Materias:
Liver Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258622/
https://www.ncbi.nlm.nih.gov/pubmed/37313239
http://dx.doi.org/10.17925/EE.2023.19.1.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258622/
https://www.ncbi.nlm.nih.gov/pubmed/37313239
http://dx.doi.org/10.17925/EE.2023.19.1.60

Ejemplares similares